News

3 June 2011
Cambridge based biotech raises further £1m to develop E. coli fighting agent

26 October 2010
As SASPject enters phase II Phico Therapeutics announces Dr Anthony F. Martin as Board Chairman

2 June 2010
Phico Therapeutics today announces the successful completion of a phase I trial showing that their new antibiotic, SASPject PT1.2, is safe and well tolerated in healthy human volunteers. Plans for a phase II trial to assess efficacy are already underway.

25 March 2010
Phico Therapeutics raises a further £1.8 M investment to accelerate development of a new class of antibiotics targeting superbugs

18 September 2009
Wellcome Trust Award-Winning Company Phico Therapeutics Releases New SASPject™ PT1.2 Efficacy Data at ICCAC

28 January 2009
Phico Therapeutics receives £1 million Award from The Wellcome Trust to take anti-MRSA nasal product through early clinical trials.

19 April 2008
New Antibiotic Class proves effective against MRSA

29 March 2007
Dr Robert Nolan, ex Director of NeuTec Pharma, joins the Phico Therapeutics' Board

11 January 2007
Phico Therapeutics raises £1.5 million for clinical trials with its anti-MRSA product

19 September 2005
Phico Therapeutics - successful fundraising

12 January 2005
Phico Therapeutics has expanded...

19 August 2004
Phico Therapeutics - successful fundraising allows company to develop novel treatment for superbug, MRSA

1 August 2002
Phico Therapeutics - New investment supports development of anti-MRSA technology